Momenta Pharma sues Teva for enoxaparin patent infringement

3 December 2010

US drugmaker Momenta Pharmaceuticals (Nasdaq: MNTA) announced that it has sued Israeli generics major Teva Pharmaceutical Industries in the US District Court for the District of Massachusetts for infringement of two Momenta patents.

The patents cover the company's innovative methods of producing enoxaparin sodium, which assure that the commercial product meets standards for identity and quality. One patent, US Patent No 7,790,466, is related to methods of processing enoxaparin to determine the presence of certain tetrasaccharide structures. The second patent, US Patent No 7,575,886, is related to methods of analyzing enoxaparin for the presence of a certain structural signature.

"Momenta has made a substantial investment in the development of novel methods that make it possible to assure the quality of complex products," stated Craig Wheeler, president and chief executive of Momenta, adding: "We intend to vigorously enforce our patent rights to protect our investment in innovative science."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK